The potential use of cyclophilin A (CypA) as a monitoring biomarker and possible therapeutic target in pediatric diffuse intrinsic pontine gliomas was supported by Saratsis et al. They also proposed using dimethylarginine dimethylaminohydrolase 1 (DDAH1) as a prognostic factor and indicator of glioma aggressiveness [78]. The gene discussed is DDAH1; the disease is glioma.